Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYCOMEN CD3
- Development stage
- Unknown
- Lead developer
- Spansa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LYCOMEN CD3 is a combination dietary supplement marketed by Spansa Pharmaceuticals. It is formulated as a tablet containing a blend of essential vitamins and minerals, including benfotiamine, calcium carbonate, zinc, methylcobalamin, and vitamin D3 (cholecalciferol). The supplement is designed to support overall health, bone strength, nerve function, and metabolic processes. Specifically, calcium and vitamin D3 promote bone mineralization and skeletal health, while methylcobalamin and benfotiamine support the nervous system and neurological function. Zinc is included to support immune function and cellular health.
- Brand names
- LYCOMEN CD3Lycomen-CD3Lycomen-CD-3Lycomen-CD 3
- Other names
- benfotiamine + calcium + cholecalciferol + methylcobalamin + zinc
02
Targets
GPR39 (G protein-coupled receptor 39)VDR (Vitamin D receptor)MTR (Methionine synthase)CaSR (Extracellular calcium-sensing receptor)TKT (Transketolase)
Beyond the preview
Go deeper on LYCOMEN CD3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYCOMEN CD3.